Cargando…
Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
BACKGROUND: There is no standard adjuvant chemotherapy to prevent recurrent cholangiocarcinoma (CCA), a rare cancer with poor prognosis. We assessed the efficacy and safety of GEMOX on intrahepatic and hilar CCA with high-risk factors after curative surgery. PATIENTS AND METHODS: Twenty two patients...
Autores principales: | Paule, Bernard, Andreani, Paola, Bralet, Marie-Pierre, Guettier, Catherine, Adam, René, Castaing, Denis, Azoulay, Daniel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872598/ |
Ejemplares similares
-
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006) -
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013) -
Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
por: Lagenfelt, Hanna, et al.
Publicado: (2021) -
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020) -
Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)